Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction

키워드

참고문헌 (146)

1. "The top 10 causes of death" (2020)[URL]
2. Ross R, "Atherosclerosis--an inflammatory disease", N Engl J Med, 340, pp.115~126 (1999)
3. Ravnskov U, "Is atherosclerosis caused by high cholesterol?", QJM, 95, pp.397~403 (2002)
4. Wang I, "Assessing the practical differences in LDL-C estimates calculated by Friedewald, Martin", Hopkins, or NIH equation 2 : an observation cross-sectional study, 2023, pp.12, 252~266
5. "Medline trend: automated yearly statistics of PubMed results for any query" (2004)[URL]
6. Razny U, "Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes", Diabetes Metab Res Rev, 33, pp.e2862~ (2017)
7. Reyes-Garcia R, "Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes", Diabetes Metab, 38, pp.76~81 (2012)
8. Ogawa-Furuya N, "Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus", Osteoporos Int, 24, pp.2223~2230 (2013)
9. Evrard S, "Vascular calcification : from pathophysiology to biomarkers", Clin Chim Acta, 438, pp.401~414 (2015)
10. Zoch ML, "New insights into the biology of osteocalcin", Bone, 82, pp.42~49 (2016)
11. Wen L, "Vitamin K-dependent proteins involved in bone and cardiovascular health(Review)", Mol Med Rep, 18, pp.3~15 (2018)
12. Seidu S, "Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes : systematic review and meta-analysis", Scand Cardiovasc J, 53, pp.286~295 (2019)
13. Jung CH, "The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase", Akt signaling pathway, 2013, pp.62, 1250~1257
14. Gössl M, "Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis", J Am Coll Cardiol, 52, pp.1314~1325 (2008)
15. Flammer AJ, "Osteocalcin positive CD133+", CD34-, Eur Heart J, pp.2012, 33[DOI]
16. Fadini GP, "Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus", J Am Coll Cardiol, 45, pp.1449~1457 (2005)
17. Lee NK, "Endocrine regulation of energy metabolism by the skeleton", Cell, 130, pp.456~469 (2007)
18. Ferron M, "Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice", Proc Natl Acad Sci U S A, 105, pp.5266~5270 (2008)
19. Millar SA, "Osteocalcin, vascular calcification, and atherosclerosis : a systematic review and meta-analysis", Front Endocrinol(Lausanne), 8, pp.183~ (2017)
20. Urano T, "Low serum osteocalcin concentration is associated with incident type 2 diabetes mellitus in Japanese women", J Bone Miner Metab, 36, pp.470~477 (2018)
21. Kanazawa I, "Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus", J Clin Endocrinol Metab, 94, pp.45~49 (2009)
22. Ye X, "Osteocalcin and risks of incident diabetes and diabetic kidney disease : a 4. 6-year prospective cohort study", Diabetes Care, 45, pp.830~836 (2022)
23. Sheng L, "Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes", Cardiovasc Diabetol, 12, pp.22~ (2013)
24. Yang R, "Relationship between serum osteocalcin levels and carotid intima-media thickness in Chinese postmenopausal women", Menopause, 20, pp.1194~1199 (2013)
25. Pennisi P, "Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels", Osteoporos Int, 15, pp.389~395 (2004)
26. Ma H, "Serum levels of osteocalcin in relation to glucose metabolism and carotid atherosclerosis in Chinese middle-aged and elderly male adults : the Shanghai Changfeng Study", Eur J Intern Med, 25, pp.259~264 (2014)
27. Yeap BB, "Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study", Osteoporos Int, 23, pp.599~606 (2012)
28. Hwang YC, "Association between the circulating total osteocalcin level and the development of cardiovascular disease in middle-aged men : a mean 8. 7-year longitudinal follow-up study", J Atheroscler Thromb, 22, pp.136~143 (2015)
29. Jia F, "Osteocalcin and abdominal aortic calcification in hemodialysis patients : an observational cross-sectional study", Front Endocrinol(Lausanne), 12, pp.620350~ (2021)
30. Beavan SR, "Ethnic differences in osteocalcin γ-carboxylation, plasma phylloquinone(vitamin K1)and apolipoprotein E genotype", Eur J Clin Nutr, 59, pp.72~81 (2005)
31. Gafni Y, "Circadian rhythm of osteocalcin in the maxillomandibular complex", J Dent Res, 88, pp.45~50 (2009)
32. Garnett ER, "Emerging biological functions of ribonuclease 1 and angiogenin", Crit Rev Biochem Mol Biol, 57, pp.244~260 (2022)
33. Sheng J, "Three decades of research on angiogenin : a review and perspective", Acta Biochim Biophys Sin(Shanghai), 48, pp.399~410 (2016)
34. Khurana R, "Role of angiogenesis in cardiovascular disease : a critical appraisal", Circulation, 112, pp.1813~1824 (2005)
35. Moreno PR, "Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta : implications for plaque vulnerability", Circulation, 110, pp.2032~2038 (2004)
36. Tello-Montoliu A, "Plasma angiogenin levels in acute coronary syndromes : implications for prognosis", Eur Heart J, 28, pp.3006~3011 (2007)
37. Heeschen C, "Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes", Circulation, 107, pp.524~530 (2003)
38. Jones CB, "Matrix metalloproteinases : a review of their structure and role in acute coronary syndrome", Cardiovasc Res, 59, pp.812~823 (2003)
39. Kręcki R, "Relationship of serum angiogenin, adiponectin and resistin levels with biochemical risk factors and the angiographic severity of three-vessel coronary disease", Cardiol J, 17, pp.599~606 (2010)
40. Jiang H, "A pilot study of angiogenin in heart failure with preserved ejection fraction : a novel potential biomarker for diagnosis and prognosis?", J Cell Mol Med, 18, pp.2189~2197 (2014)
41. Patel JV, "Elevated angiogenin levels in chronic heart failure", Ann Med, 40, pp.474~479 (2008)
42. Huang L, "Carotid artery color Doppler ultrasonography and plasma levels of lipoprotein-associated phospholipase A2 and cystatin C in arteriosclerotic cerebral infarction", J Int Med Res, 47, pp.4389~4396 (2019)
43. Cao J, "Lipoprotein-associated phospholipase A(2)interacts with phospholipid vesicles via a surface-disposed hydrophobic α-helix", Biochemistry, 50, pp.5314~5321 (2011)
44. Law SH, "An updated review of lysophosphatidylcholine metabolism in human diseases", Int J Mol Sci, 20, pp.1149~ (2019)
45. Tselepis AD, "Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a)functionality and pathophysiological role", J Biomed Res, 31, pp.13~22 (2018)
46. Maiolino G, "Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications", World J Cardiol, 7, pp.609~620 (2015)
47. Silva IT, "Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2(Lp-PLA2) : a review", Lipids Health Dis, 10, pp.170~ (2011)
48. Lara-Guzmán OJ, "Oxidized LDL triggers changes in oxidative stress and inflammatory biomarkers in human macrophages", Redox Biol, 15, pp.1~11 (2018)
49. Thompson A, "Lipoprotein-associated phospholipase A(2)and risk of coronary disease, stroke, and mortality : collaborative analysis of 32 prospective studies", Lancet, 375, pp.1536~1544 (2010)
50. Gong HP, "Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis", Lipids Health Dis, 10, pp.13~ (2011)
51. Vittos O, "Lipoprotein-associated phospholipase A2(Lp-PLA2) : a review of its role and significance as a cardiovascular biomarker", Biomarkers, 17, pp.289~302 (2012)
52. Koenig W, "Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population : results from the 14-year follow-up of a large cohort from southern Germany", Circulation, 110, pp.1903~1908 (2004)
53. Oei HH, "Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke : the Rotterdam Study", Circulation, 111, pp.570~575 (2005)
54. Packard CJ, "Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease", N Engl J Med, 343, pp.1148~1155 (2000)
55. Daniels LB, "Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population : the Rancho Bernardo Study", J Am Coll Cardiol, 51, pp.913~919 (2008)
56. Liu H, "Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis : a cross-sectional study", J Cell Mol Med, 22, pp.5145~5150 (2018)
57. Ballantyne CM, "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities(ARIC)study", Circulation, 109, pp.837~842 (2004)
58. Melander O, "Novel and conventional biomarkers for prediction of incident cardiovascular events in the community", JAMA, 302, pp.49~57 (2009)
59. Sofogianni A, "Lipoprotein-associated phospholipase A2 and coronary heart disease", Curr Pharm Des, 24, pp.291~296 (2018)
60. Ge PC, "Synergistic effect of lipoprotein-associated phospholipase A2 with classical risk factors on coronary heart disease : a multi-ethnic study in China", Cell Physiol Biochem, 40, pp.953~968 (2016)
61. Garg PK, "Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort : the multi ethnic study of atherosclerosis", Atherosclerosis, 241, pp.176~182 (2015)
62. Mehta RS, "Association between plasma levels of macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality", Gastroenterology, 149, pp.614~622 (2015)
63. Wollert KC, "Growth differentiation factor 15 as a biomarker in cardiovascular disease", Clin Chem, 63, pp.140~151 (2017)
64. Bootcov MR, "MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily", Proc Natl Acad Sci U S A, 94, pp.11514~11519 (1997)
65. Fluschnik N, "Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease", PLoS One, 13, pp.e0197497~ (2018)
66. Wollert KC, "Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome", Circulation, 115, pp.962~971 (2007)
67. Kempf T, "Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction", Eur Heart J, 28, pp.2858~2865 (2007)
68. Kempf T, "Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease : results from the AtheroGene study", Circ Cardiovasc Genet, 2, pp.286~292 (2009)
69. Li M, "Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease", Cardiovasc Diabetol, 19, pp.120~ (2020)
70. Ho JE, "Protein biomarkers of cardiovascular disease and mortality in the community", J Am Heart Assoc, 7, pp.e008108~ (2018)
71. Anand IS, "Serial measurement of growth-differentiation factor-15 in heart failure : relation to disease severity and prognosis in the Valsartan Heart Failure Trial", Circulation, 122, pp.1387~1395 (2010)
72. Jha D, "Prognostic role of soluble ST2 in acute coronary syndrome with diabetes", Eur J Clin Invest, 48, pp.e12994~ (2018)
73. Liu X, "Soluble ST2 for prediction of clinical outcomes in patients with ST-segment elevation myocardial infarction receiving primary PCI", Int Heart J, 60, pp.19~26 (2019)
74. Jenkins WS, "Prognostic value of soluble ST2 after myocardial infarction : a community perspective", Am J Med, 130, pp.1112~ (2017)
75. Lassus J, "Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure : the Multinational Observational Cohort on Acute Heart Failure(MOCA)study", Int J Cardiol, 168, pp.2186~2194 (2013)
76. Januzzi JL Jr, "Measurement of the interleukin family member ST2 in patients with acute dyspnea : results from the PRIDE(Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department)study", J Am Coll Cardiol, 50, pp.607~613 (2007)
77. Socrates T, "Interleukin family member ST2 and mortality in acute dyspnoea", J Intern Med, 268, pp.493~500 (2010)
78. Tian L, "Correlation between galectin-3 and adverse outcomes in myocardial infarction patients : a meta-analysis", Cardiol Res Pract, 2020, pp.7614327~ (2020)
79. Cardoso AL, "Towards frailty biomarkers : candidates from genes and pathways regulated in aging and age-related diseases", Ageing Res Rev, 47, pp.214~277 (2018)
80. Dong R, "Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy(review)", Int J Mol Med, 41, pp.599~614 (2018)
81. Li M, "Value of galectin-3 in acute myocardial infarction", Am J Cardiovasc Drugs, 20, pp.333~342 (2020)
82. Bayes-Genis A, "Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification : ST2 versus galectin-3", J Am Coll Cardiol, 63, pp.158~166 (2014)
83. Papaspyridonos M, "Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction", Arterioscler Thromb Vasc Biol, 28, pp.433~440 (2008)
84. Oyenuga A, "Plasma galectin-3 and sonographic measures of carotid atherosclerosis in the atherosclerosis risk in communities study", Angiology, 70, pp.47~55 (2019)
85. Kusaka H, "Clinical significance of plasma galectin-3 in patients with coronary artery disease", Int J Cardiol, 201, pp.532~534 (2015)
86. Wang TJ, "Multiple biomarkers for the prediction of first major cardiovascular events and death", N Engl J Med, 355, pp.2631~2639 (2006)
87. Gagno G, "Galectin 3 and galectin 3 binding protein improve the risk stratification after myocardial infarction", J Clin Med, 8, pp.570~ (2019)
88. Święcki P, "Galectin-3 as the prognostic factor of adverse cardiovascular events in long-term follow up in patients after myocardial infarction-a pilot study", J Clin Med, 9, pp.1640~ (2020)
89. Asleh R, "Galectin-3 levels and outcomes after myocardial infarction : a population-based study", J Am Coll Cardiol, 73, pp.2286~2295 (2019)
90. Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
91. Kakkar R, "The IL-33", ST2 pathway : therapeutic target and novel biomarker, 2008, pp.7, 827~840
92. Bayés-Genis A, "ST2 in heart failure", Circ Heart Fail, 11, pp.e005582~ (2018)
93. Tsigkou V, "The predictive role for ST2 in patients with acute coronary syndromes and heart failure", Curr Med Chem, 27, pp.4479~4493 (2020)
94. Pascual-Figal DA, "The biology of ST2 : the international ST2 consensus panel", Am J Cardiol, 115(Suppl), pp.3B~7B (2015)
95. Wallentin L, "Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease : a retrospective study", PLoS Med, 18, pp.e1003513~ (2021)
96. Somuncu MU, "The elevated soluble ST2 predicts no-reflow phenomenon in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention", J Atheroscler Thromb, 26, pp.970~978 (2019)
97. Pérez-Martínez MT, "Noncardiac production of soluble ST2 in ST-segment elevation myocardial infarction", J Am Coll Cardiol, 72, pp.1429~1430 (2018)
98. Pusceddu I, "ST2 and the ST2", IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans, 2019, pp.495, 493~500
99. Birney E, "Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project", Nature, 447, pp.799~816 (2007)
100. Nemeth K, "Non-coding RNAs in disease : from mechanisms to therapeutics", Nat Rev Genet, 25, pp.211~232 (2024)
101. Uszczynska-Ratajczak B, "Towards a complete map of the human long non-coding RNA transcriptome", Nat Rev Genet, 19, pp.535~548 (2018)
102. e S, "The circulating non-coding RNA landscape for biomarker research : lessons and prospects from cardiovascular diseases", Acta Pharmacol Sin, 39, pp.1085~1099 (2018)
103. Shang R, "microRNAs in action : biogenesis, function and regulation", Nat Rev Genet, 24, pp.816~833 (2023)
104. Li G, "CCAR1 5′ UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance", Cell Res, 26, pp.655~673 (2016)
105. Kozomara A, "miRBase : from microRNA sequences to function", Nucleic Acids Res, 47, pp.D155~ (2019)
106. Tanase DM, "Current knowledge of microRNAs(miRNAs)in acute coronary syndrome(ACS) : ST-elevation myocardial infarction(STEMI)", Life(Basel), 11, pp.1057~ (2021)
107. Hosen MR, "MicroRNAs as master regulators of atherosclerosis : from pathogenesis to novel therapeutic options", Antioxid Redox Signal, 33, pp.621~644 (2020)
108. Wang GK, "Circulating microRNA : a novel potential biomarker for early diagnosis of acute myocardial infarction in humans", Eur Heart J, 31, pp.659~666 (2010)
109. Liu X, "Plasma miR-1, miR-208, miR-499 as potential predictive biomarkers for acute myocardial infarction : an independent study of Han population", Exp Gerontol, 72, pp.230~238 (2015)
110. Liu H, "Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease", Biomed Rep, 5, pp.332~336 (2016)
111. Kuwabara Y, "Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage", Circ Cardiovasc Genet, 4, pp.446~454 (2011)
112. Gacoń J, "Decision-making microRNAs(miR-124, -133a", b, -34a and-134)in patients with occluded target vessel in acute coronary syndrome, 2016, pp.74, 280~288
113. Gao H, "Plasma levels of microRNA-145 are associated with severity of coronary artery disease", PLoS One, 10, pp.e0123477~ (2015)
114. Xue S, "Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p are novel biomarkers for diagnosis of acute myocardial infarction", Front Physiol, 10, pp.123~ (2019)
115. Zhao Y, "Circulating mir-483-5p as a novel diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after PCI", BMC Cardiovasc Disord, 23, pp.360~ (2023)
116. Zhang Y, "Association between circulating microRNA-208a and severity of coronary heart disease", Scand J Clin Lab Invest, 77, pp.379~384 (2017)
117. Guo JF, "Association between elevated plasma microRNA-223 content and severity of coronary heart disease", Scand J Clin Lab Invest, 78, pp.373~378 (2018)
118. Devaux Y, "Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain", J Intern Med, 277, pp.260~271 (2015)
119. Schulte C, "miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease", PLoS One, 10, pp.e0145930~ (2015)
120. Dong YM, "Prediction of long-term outcome after acute myocardial infarction using circulating miR-145", Scand J Clin Lab Invest, 75, pp.85~91 (2015)
121. Boštjančič E, "Down-regulation of miR-133a", b in patients with myocardial infarction correlates with the presence of ventricular fibrillation, 2018, pp.99, 65~71
122. Hosen MR, "Circulating microRNA-122-5p is associated with a lack of improvement in left ventricular function after transcatheter aortic valve replacement and regulates viability of cardiomyocytes through extracellular vesicles", Circulation, 146, pp.1836~1854 (2022)
123. Mishra PK, "P59 H2S ameliorates homocysteine mediated attenuation of miR-133a and β2-AR in diabetic hearts", Nitric Oxide, 27, pp.S38~ (2012)
124. Xu C, "β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression", J Mol Cell Cardiol, 75, pp.111~121 (2014)
125. Hinkel R, "AntimiR-21 prevents myocardial dysfunction in a pig model of ischemia", reperfusion injury, 2020, pp.75, 1788~1800
126. Carvalho A, "Inhibition of miR-195-3p protects against cardiac dysfunction and fibrosis after myocardial infarction", Int J Cardiol, 387, pp.131128~ (2023)
127. Liu X, "Significant association between functional microRNA polymorphisms and coronary heart disease susceptibility : a comprehensive meta-analysis involving 16484 subjects", Oncotarget, 8, pp.5692~5702 (2017)
128. Chen C, "Overview of 8 circulating microRNAs and their functions as major biomarkers for cardiovascular diseases", Clin Pract Rev Metaanal, 7, pp.e924530~ (2020)
129. Condrat CE, "miRNAs as biomarkers in disease : latest findings regarding their role in diagnosis and prognosis", Cells, 9, pp.276~ (2020)
130. Chistiakov DA, "Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology(with focus on myocardial infarction)", J Mol Cell Cardiol, 94, pp.107~121 (2016)
131. Tang Y, "MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2", Int Heart J, 50, pp.377~387 (2009)
132. Wang L, "MicroRNA-1 aggravates cardiac oxidative stress by post-transcriptional modification of the antioxidant network", Cell Stress Chaperones, 20, pp.411~420 (2015)
133. Li AY, "miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes", Mol Cell Biochem, 400, pp.173~181 (2015)
134. Dakhlallah D, "MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarct heart", J Cardiovasc Pharmacol, 65, pp.241~251 (2015)
135. Sang HQ, "MicroRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats", Biomed Pharmacother, 71, pp.185~189 (2015)
136. García R, "Circulating levels of miR-133a predict the regression potential of left ventricular hypertrophy after valve replacement surgery in patients with aortic stenosis", J Am Heart Assoc, 2, pp.e000211~ (2013)
137. Xiao Y, "MicroRNA-133a and myocardial infarction", Cell Transplant, 28, pp.831~838 (2019)
138. Yang B, "Control of cardiac excitability by microRNAs", Cardiovasc Res, 79, pp.571~580 (2008)
139. Cordes KR, "miR-145 and miR-143 regulate smooth muscle cell fate and plasticity", Nature, 460, pp.705~710 (2009)
140. Liu Y, "Roles of microRNA-122 in cardiovascular fibrosis and related diseases", Cardiovasc Toxicol, 20, pp.463~473 (2020)
141. Varzideh F, "Cardiac remodeling after myocardial infarction : functional contribution of microRNAs to inflammation and fibrosis", Front Cardiovasc Med, 9, pp.863238~ (2022)
142. Li N, "miR-133 : a suppressor of cardiac remodeling?", Front Pharmacol, 9, pp.903~ (2018)
143. Thum T, "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts", Nature, 456, pp.980~984 (2008)
144. Kaudewitz D, "Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease", Thromb Haemost, 110, pp.609~615 (2013)
145. Sunderland N, "MicroRNA biomarkers and platelet reactivity : the clot thickens", Circ Res, 120, pp.418~435 (2017)
146. Schulte C, "Comparative analysis of circulating noncoding RNAs versus protein biomarkers in the detection of myocardial injury", Circ Res, 125, pp.328~340 (2019)

관련 논문AI추천